SGLT2 inhibitor improves kidney function and morphology by regulating renal metabolism in mice with diabetic kidney disease
Journal of Diabetes and its Complications · 2024
DOI: 10.1016/j.jdiacomp.2023.108652 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes and its Complications, 2024. Verfasst von Chunru Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Key Laboratory of Endocrinology National Health Commission, Peking Union Medical College Hospital, Peking Union Medical …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Diabetic Nephropathies, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Diabetic kidney disease (DKD) is a secondary complication of diabetes mellitus and a leading cause of chronic kidney disease. AIM: To investigate the impact of long-term canagliflozin treatment on DKD and elucidate its underlying mechanism. METHODS: DKD model was established using high-fat diet and streptozotocin in male C57BL/6J mice (n = 30). Mice were divided into five groups and treated for 12 weeks. 1) normal control mice, 2) DKD model, 3) mice treated low-dose of canagliflozin, 4) high-dose of canagliflozin and 5) β-hydroxybutyrate. Mice kidney morphology and function were evaluated, and a metabolomics analysis was performed. RESULTS: Canagliflozin treatment reduced blood creatinine and urine nitrogen levels and improved systemic insulin sensitivity and glucose tolerance in diabetic mice. Additionally, a decrease in histological lesions including collagen and lipid deposition in the kidneys was observed. β-hydroxybutyrate treatment did not yield a comparable outcome. The metabolomics analysis revealed that canagliflozin induced alterations in amino acid metabolism profiles in the renal tissue of diabetic mice. CONCLUSION: Canagliflozin protects the kidneys of diabetic mice by increasing the levels of essential amino acids, promoting mitochondrial homeostasis, mitigating oxidative stress, and stimulating the amino acid-dependent tricarboxylic acid cycle.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Key Laboratory of Endocrinology National Health Commission, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
- Department of Medical Research Center, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China. Electronic address: liujieying@vip.163.com.
- Department of Endocrinology, Key Laboratory of Endocrinology National Health Commission, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China. E…
Zitieren
APA
Yang, C., Xiao, C., Zhai, X., Liu, J., & Yu, M. (2024). SGLT2 inhibitor improves kidney function and morphology by regulating renal metabolism in mice with diabetic kidney disease. Journal of Diabetes and its Complications. https://doi.org/10.1016/j.jdiacomp.2023.108652
Vancouver
Yang C, Xiao C, Zhai X, Liu J, Yu M. SGLT2 inhibitor improves kidney function and morphology by regulating renal metabolism in mice with diabetic kidney disease. Journal of Diabetes and its Complications. 2024. doi:10.1016/j.jdiacomp.2023.108652
BibTeX
@article{Yang2024,
author = {Yang, Chunru and Xiao, Cheng and Zhai, Xiaojun and Liu, Jieying and Yu, Miao},
title = {SGLT2 inhibitor improves kidney function and morphology by regulating renal metabolism in mice with diabetic kidney disease},
journal = {Journal of Diabetes and its Complications},
year = {2024},
doi = {10.1016/j.jdiacomp.2023.108652}
}
EUVIMED